T/FIF, a New Plateau | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
T/FIF, a New Plateau

An SI Board Since February 2000

Posts	SubjectMarks	Bans
2243	64	0

Emcee: scaram(o)uche	Type: Unmoderated

Introduction Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
1918	Order, day, placed for 1K shares of XNVA at 1.92. Current ask is 2.00. Thanks	scaram(o)uche	-	4/4/2003
1917	Thanks for the suggestion, Tom. Yes, we've already got it in both portfolio	scaram(o)uche	-	4/4/2003
1916	400 shares ARDM added to "2000" at current ask of 1.16. 100 shares MO	scaram(o)uche	-	4/4/2003
1915	<i> Most bookmarked [company specific] appears to be LGND</i> Sugge	Biomaven	-	4/4/2003
1914	Not a lurker, but will offer a dark horse, "got-to-be-patient" suggest	tuck	-	4/4/2003
1913	What about TELK? Not much news recently, good or bad, but TLK-286 Phase 3 seems	tom pope	-	4/4/2003
1912	<B>Welcome, all of you lurkers out there! Any ideas for what we should spe	Allan Harris	-	4/4/2003
1911	<i>Least bookmarked</i> ARQL, 2. Subject 53848 So far. :-)	nigel bates	-	4/4/2003
1910	>> After the valuation thread, it looks like the BVF thread and then this	scaram(o)uche	-	4/3/2003
1909	I noticed now that whenever you click on a subject title, you can see the number	tuck	-	4/3/2003
1908	keep it coming, please. (eom)	scaram(o)uche	-	4/3/2003
1907	>> Spectrum Pharmaceuticals (SPPI)>> Spectrum had a fairly good day	Icebrg	-	4/3/2003
1906	1K shares each of NBSC sold from "2000" at current bid of 5.10, <b&	scaram(o)uche	-	4/3/2003
1905	>> Adding 1K shares to "2000" at current ask of 2.85 << R	scaram(o)uche	-	4/3/2003
1904	>> vitaxin is already in the clinic, both indications << Oh. I kne	scaram(o)uche	-	4/2/2003
1903	No doubt about it and partners probably fund about 1/3 of amev's spend rate.	rkrw	-	4/2/2003
1902	however, rkrw, it prevents some burn in this market	Biotech Jim	-	4/2/2003
1901	vitaxin is already in the clinic, both indications, but point taken. Young says	rkrw	-	4/2/2003
1900	>> Will a medimmune pull through and have 3 amev derived compounds in the	scaram(o)uche	-	4/2/2003
1899	RKRW, I think i saw that answer somewhere before :-) Thanks for saving me Ste	dalroi	-	4/2/2003
1898	I once interviewed for V.P. R&D, back when they were Ixsys. They didn't	scaram(o)uche	-	4/2/2003
1897	My amev thoughts: $56M market cap, $51M in cash, roughly $35M in projected cas	rkrw	-	4/2/2003
1896	AMEV: I might have some of this not quite right.... proprietary programs (prec	keokalani'nui	-	4/2/2003
1895	I'll take that one. Other projects are progressing, but not as far along as	tuck	-	4/2/2003
1894	Rick i would like to pass that question to RKRW :-) cheers Stefaan	dalroi	-	4/2/2003

Go to reply# or date (mm/dd/yy):